Top Markets
Coin of the day
Reviva Pharmaceuticals Holdings, Inc. Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc.

RVPHW
Rangering i aksjer #39800
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical... Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for diseases with substantial unmet medical needs. Their pipeline targets disorders within the central nervous system, respiratory, cardiovascular, metabolic, and inflammatory disease categories. The company's leading drug candidate, brilaroxazine (RP5063), is currently in Phase III clinical trials for the treatment of schizophrenia. This compound has also completed Phase I trials for a diverse set of conditions, including bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, the behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. Furthermore, Reviva is advancing RP1208, which is in pre-clinical development for depression and obesity. Founded in 2018, the company is headquartered in Cupertino, California.
Aksjekurs
$0.003
Sist synkronisert: 2025-12-12
Markedsverdi
$343.91K
Endring (1 dag)
-16.67%
Endring (1 år)
-90.23%
Land
US
Handel Reviva Pharmaceuticals Holdings, Inc. (RVPHW)

Kategori

EPS for Reviva Pharmaceuticals Holdings, Inc. (RVPHW)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Reviva Pharmaceuticals Holdings, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Reviva Pharmaceuticals Holdings, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter